For: | Panayiotakopoulos GD, Papadimitriou DT. Rifampicin for COVID-19. World J Virol 2022; 11(2): 90-97 [PMID: 35433334 DOI: 10.5501/wjv.v11.i2.90] |
---|---|
URL: | https://www.wjgnet.com/2220-3249/full/v11/i2/90.htm |
Number | Citing Articles |
1 |
Marwa El-Azazy, Ahmed S. El-Shafie, Reem Al-Mulla, Siham S. Hassan, Hassan I. Nimir. Enhanced adsorptive removal of rifampicin and tigecycline from single system using nano-ceria decorated biochar of mango seed kernel. Heliyon 2023; 9(5): e15802 doi: 10.1016/j.heliyon.2023.e15802
|
2 |
Ozlem Celik Aydin, Sonay Aydın, Sureyya Barun. Possible agent for COVID-19 treatment: Rifampicin. World Journal of Virology 2022; 11(5): 391-393 doi: 10.5501/wjv.v11.i5.391
Abstract(384) |
Core Tip(390) |
Full Article(HTML)(1473)
|
Full Article (PDF)-567K(113)
|
Full Article (Word)-105K(39)
|
Audio-48K(3)
|
Peer-Review Report-227K(53)
|
Answering Reviewers-76K(45)
|
Times Cited (0)
|
Total Visits (4201)
|
Open
|
3 |
Bhoomika Patel, Anita Sinha, Mamatarani Verma, Dhwani Patel, Jigar Desai. A Study of COVID-19 Infected Patients with Tuberculosis as Comorbidity and on Antitubercular Drug Therapy. Indian Journal of Respiratory Care 2023; 12(3): 239 doi: 10.5005/jp-journals-11010-1058
|
4 |
Jasmine Arya, Sweety Dahiya, Anil Kumar Chhillar. Multidrug-resistant Tuberculosis and its Implication with COVID-19. Coronaviruses 2023; 4(3) doi: 10.2174/2666796704666230822113632
|